Biologics and Biosimilars Industry Research Report 2024
Summary
A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.
A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.
According to APO Research, the global Biologics and Biosimilars market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.
North American market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global manufacturers of Biologics and Biosimilars include Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly and Novartis, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Biologics and Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biologics and Biosimilars.
The report will help the Biologics and Biosimilars manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Biologics and Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biologics and Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics and Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Biologics and Biosimilars manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Biologics and Biosimilars by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Biologics and Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.
A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.
According to APO Research, the global Biologics and Biosimilars market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.
North American market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Biologics and Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global manufacturers of Biologics and Biosimilars include Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly and Novartis, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Biologics and Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biologics and Biosimilars.
The report will help the Biologics and Biosimilars manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Biologics and Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biologics and Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
- Roche
- Amgen
- AbbVie
- Sanofi-Aventis
- Johnson & Johnson
- Pfizer
- Novo Nordisk
- Eli Lilly
- Novartis
- Merck
- 3sbio
- Changchun High Tech
- CP Guojian
- Biotech
- Gelgen
- Innovent
- Dong Bao
- Ganlee
- United Laboratories
- Monoclonal Antibodies
- Interferon
- Erythropoietin
- Insulin
- Vaccines
- Others
- Tumor
- Diabetes
- Cardiovascular
- Hemophilia
- Others
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics and Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Biologics and Biosimilars manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Biologics and Biosimilars by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Biologics and Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
1 PREFACE
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Biologics and Biosimilars Market Size (2019-2030) & (US$ Million)
2.2.2 Global Biologics and Biosimilars Sales (2019-2030)
2.2.3 Global Biologics and Biosimilars Market Average Price (2019-2030)
2.3 Biologics and Biosimilars by Type
2.3.1 Market Value Comparison by Type (2019 VS 2023 VS 2030) & (US$ Million)
2.3.2 Monoclonal Antibodies
2.3.3 Interferon
2.3.4 Erythropoietin
2.3.5 Insulin
2.3.6 Vaccines
2.3.7 Others
2.4 Biologics and Biosimilars by Application
2.4.1 Market Value Comparison by Application (2019 VS 2023 VS 2030) & (US$ Million)
2.4.2 Tumor
2.4.3 Diabetes
2.4.4 Cardiovascular
2.4.5 Hemophilia
2.4.6 Others
3 MARKET COMPETITIVE LANDSCAPE BY MANUFACTURERS
3.1 Global Biologics and Biosimilars Market Competitive Situation by Manufacturers (2019 Versus 2023)
3.2 Global Biologics and Biosimilars Sales (K Units) of Manufacturers (2019-2024)
3.3 Global Biologics and Biosimilars Revenue of Manufacturers (2019-2024)
3.4 Global Biologics and Biosimilars Average Price by Manufacturers (2019-2024)
3.5 Global Biologics and Biosimilars Industry Ranking, 2022 VS 2023 VS 2024
3.6 Global Manufacturers of Biologics and Biosimilars, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Biologics and Biosimilars, Product Type & Application
3.8 Global Manufacturers of Biologics and Biosimilars, Date of Enter into This Industry
3.9 Global Biologics and Biosimilars Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 MANUFACTURERS PROFILED
4.1 Roche
4.1.1 Roche Company Information
4.1.2 Roche Business Overview
4.1.3 Roche Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.1.4 Roche Biologics and Biosimilars Product Portfolio
4.1.5 Roche Recent Developments
4.2 Amgen
4.2.1 Amgen Company Information
4.2.2 Amgen Business Overview
4.2.3 Amgen Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.2.4 Amgen Biologics and Biosimilars Product Portfolio
4.2.5 Amgen Recent Developments
4.3 AbbVie
4.3.1 AbbVie Company Information
4.3.2 AbbVie Business Overview
4.3.3 AbbVie Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.3.4 AbbVie Biologics and Biosimilars Product Portfolio
4.3.5 AbbVie Recent Developments
4.4 Sanofi-Aventis
4.4.1 Sanofi-Aventis Company Information
4.4.2 Sanofi-Aventis Business Overview
4.4.3 Sanofi-Aventis Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.4.4 Sanofi-Aventis Biologics and Biosimilars Product Portfolio
4.4.5 Sanofi-Aventis Recent Developments
4.5 Johnson & Johnson
4.5.1 Johnson & Johnson Company Information
4.5.2 Johnson & Johnson Business Overview
4.5.3 Johnson & Johnson Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.5.4 Johnson & Johnson Biologics and Biosimilars Product Portfolio
4.5.5 Johnson & Johnson Recent Developments
4.6 Pfizer
4.6.1 Pfizer Company Information
4.6.2 Pfizer Business Overview
4.6.3 Pfizer Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.6.4 Pfizer Biologics and Biosimilars Product Portfolio
4.6.5 Pfizer Recent Developments
4.7 Novo Nordisk
4.7.1 Novo Nordisk Company Information
4.7.2 Novo Nordisk Business Overview
4.7.3 Novo Nordisk Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.7.4 Novo Nordisk Biologics and Biosimilars Product Portfolio
4.7.5 Novo Nordisk Recent Developments
4.8 Eli Lilly
4.8.1 Eli Lilly Company Information
4.8.2 Eli Lilly Business Overview
4.8.3 Eli Lilly Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.8.4 Eli Lilly Biologics and Biosimilars Product Portfolio
4.8.5 Eli Lilly Recent Developments
4.9 Novartis
4.9.1 Novartis Company Information
4.9.2 Novartis Business Overview
4.9.3 Novartis Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.9.4 Novartis Biologics and Biosimilars Product Portfolio
4.9.5 Novartis Recent Developments
4.10 Merck
4.10.1 Merck Company Information
4.10.2 Merck Business Overview
4.10.3 Merck Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.10.4 Merck Biologics and Biosimilars Product Portfolio
4.10.5 Merck Recent Developments
4.11 3sbio
4.11.1 3sbio Company Information
4.11.2 3sbio Business Overview
4.11.3 3sbio Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.11.4 3sbio Biologics and Biosimilars Product Portfolio
4.11.5 3sbio Recent Developments
4.12 Changchun High Tech
4.12.1 Changchun High Tech Company Information
4.12.2 Changchun High Tech Business Overview
4.12.3 Changchun High Tech Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.12.4 Changchun High Tech Biologics and Biosimilars Product Portfolio
4.12.5 Changchun High Tech Recent Developments
4.13 CP Guojian
4.13.1 CP Guojian Company Information
4.13.2 CP Guojian Business Overview
4.13.3 CP Guojian Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.13.4 CP Guojian Biologics and Biosimilars Product Portfolio
4.13.5 CP Guojian Recent Developments
4.14 Biotech
4.14.1 Biotech Company Information
4.14.2 Biotech Business Overview
4.14.3 Biotech Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.14.4 Biotech Biologics and Biosimilars Product Portfolio
4.14.5 Biotech Recent Developments
4.15 Gelgen
4.15.1 Gelgen Company Information
4.15.2 Gelgen Business Overview
4.15.3 Gelgen Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.15.4 Gelgen Biologics and Biosimilars Product Portfolio
4.15.5 Gelgen Recent Developments
4.16 Innovent
4.16.1 Innovent Company Information
4.16.2 Innovent Business Overview
4.16.3 Innovent Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.16.4 Innovent Biologics and Biosimilars Product Portfolio
4.16.5 Innovent Recent Developments
4.17 Dong Bao
4.17.1 Dong Bao Company Information
4.17.2 Dong Bao Business Overview
4.17.3 Dong Bao Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.17.4 Dong Bao Biologics and Biosimilars Product Portfolio
4.17.5 Dong Bao Recent Developments
4.18 Ganlee
4.18.1 Ganlee Company Information
4.18.2 Ganlee Business Overview
4.18.3 Ganlee Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.18.4 Ganlee Biologics and Biosimilars Product Portfolio
4.18.5 Ganlee Recent Developments
4.19 United Laboratories
4.19.1 United Laboratories Company Information
4.19.2 United Laboratories Business Overview
4.19.3 United Laboratories Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.19.4 United Laboratories Biologics and Biosimilars Product Portfolio
4.19.5 United Laboratories Recent Developments
5 GLOBAL BIOLOGICS AND BIOSIMILARS MARKET SCENARIO BY REGION
5.1 Global Biologics and Biosimilars Market Size by Region: 2019 VS 2023 VS 2030
5.2 Global Biologics and Biosimilars Sales by Region: 2019-2030
5.2.1 Global Biologics and Biosimilars Sales by Region: 2019-2024
5.2.2 Global Biologics and Biosimilars Sales by Region: 2025-2030
5.3 Global Biologics and Biosimilars Revenue by Region: 2019-2030
5.3.1 Global Biologics and Biosimilars Revenue by Region: 2019-2024
5.3.2 Global Biologics and Biosimilars Revenue by Region: 2025-2030
5.4 North America Biologics and Biosimilars Market Facts & Figures by Country
5.4.1 North America Biologics and Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
5.4.2 North America Biologics and Biosimilars Sales by Country (2019-2030)
5.4.3 North America Biologics and Biosimilars Revenue by Country (2019-2030)
5.4.4 U.S.
5.4.5 Canada
5.5 Europe Biologics and Biosimilars Market Facts & Figures by Country
5.5.1 Europe Biologics and Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
5.5.2 Europe Biologics and Biosimilars Sales by Country (2019-2030)
5.5.3 Europe Biologics and Biosimilars Revenue by Country (2019-2030)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.6 Asia Pacific Biologics and Biosimilars Market Facts & Figures by Country
5.6.1 Asia Pacific Biologics and Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
5.6.2 Asia Pacific Biologics and Biosimilars Sales by Country (2019-2030)
5.6.3 Asia Pacific Biologics and Biosimilars Revenue by Country (2019-2030)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Indonesia
5.6.11 Thailand
5.6.12 Malaysia
5.7 Latin America Biologics and Biosimilars Market Facts & Figures by Country
5.7.1 Latin America Biologics and Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
5.7.2 Latin America Biologics and Biosimilars Sales by Country (2019-2030)
5.7.3 Latin America Biologics and Biosimilars Revenue by Country (2019-2030)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa Biologics and Biosimilars Market Facts & Figures by Country
5.8.1 Middle East and Africa Biologics and Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
5.8.2 Middle East and Africa Biologics and Biosimilars Sales by Country (2019-2030)
5.8.3 Middle East and Africa Biologics and Biosimilars Revenue by Country (2019-2030)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 SEGMENT BY TYPE
6.1 Global Biologics and Biosimilars Sales by Type (2019-2030)
6.1.1 Global Biologics and Biosimilars Sales by Type (2019-2030) & (K Units)
6.1.2 Global Biologics and Biosimilars Sales Market Share by Type (2019-2030)
6.2 Global Biologics and Biosimilars Revenue by Type (2019-2030)
6.2.1 Global Biologics and Biosimilars Sales by Type (2019-2030) & (US$ Million)
6.2.2 Global Biologics and Biosimilars Revenue Market Share by Type (2019-2030)
6.3 Global Biologics and Biosimilars Price by Type (2019-2030)
7 SEGMENT BY APPLICATION
7.1 Global Biologics and Biosimilars Sales by Application (2019-2030)
7.1.1 Global Biologics and Biosimilars Sales by Application (2019-2030) & (K Units)
7.1.2 Global Biologics and Biosimilars Sales Market Share by Application (2019-2030)
7.2 Global Biologics and Biosimilars Revenue by Application (2019-2030)
7.2.1 Global Biologics and Biosimilars Sales by Application (2019-2030) & (US$ Million)
7.2.2 Global Biologics and Biosimilars Revenue Market Share by Application (2019-2030)
7.3 Global Biologics and Biosimilars Price by Application (2019-2030)
8 VALUE CHAIN AND SALES CHANNELS ANALYSIS OF THE MARKET
8.1 Biologics and Biosimilars Value Chain Analysis
8.1.1 Biologics and Biosimilars Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Biologics and Biosimilars Production Mode & Process
8.2 Biologics and Biosimilars Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Biologics and Biosimilars Distributors
8.2.3 Biologics and Biosimilars Customers
9 GLOBAL BIOLOGICS AND BIOSIMILARS ANALYZING MARKET DYNAMICS
9.1 Biologics and Biosimilars Industry Trends
9.2 Biologics and Biosimilars Industry Drivers
9.3 Biologics and Biosimilars Industry Opportunities and Challenges
9.4 Biologics and Biosimilars Industry Restraints
10 REPORT CONCLUSION
11 DISCLAIMER
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Biologics and Biosimilars Market Size (2019-2030) & (US$ Million)
2.2.2 Global Biologics and Biosimilars Sales (2019-2030)
2.2.3 Global Biologics and Biosimilars Market Average Price (2019-2030)
2.3 Biologics and Biosimilars by Type
2.3.1 Market Value Comparison by Type (2019 VS 2023 VS 2030) & (US$ Million)
2.3.2 Monoclonal Antibodies
2.3.3 Interferon
2.3.4 Erythropoietin
2.3.5 Insulin
2.3.6 Vaccines
2.3.7 Others
2.4 Biologics and Biosimilars by Application
2.4.1 Market Value Comparison by Application (2019 VS 2023 VS 2030) & (US$ Million)
2.4.2 Tumor
2.4.3 Diabetes
2.4.4 Cardiovascular
2.4.5 Hemophilia
2.4.6 Others
3 MARKET COMPETITIVE LANDSCAPE BY MANUFACTURERS
3.1 Global Biologics and Biosimilars Market Competitive Situation by Manufacturers (2019 Versus 2023)
3.2 Global Biologics and Biosimilars Sales (K Units) of Manufacturers (2019-2024)
3.3 Global Biologics and Biosimilars Revenue of Manufacturers (2019-2024)
3.4 Global Biologics and Biosimilars Average Price by Manufacturers (2019-2024)
3.5 Global Biologics and Biosimilars Industry Ranking, 2022 VS 2023 VS 2024
3.6 Global Manufacturers of Biologics and Biosimilars, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Biologics and Biosimilars, Product Type & Application
3.8 Global Manufacturers of Biologics and Biosimilars, Date of Enter into This Industry
3.9 Global Biologics and Biosimilars Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 MANUFACTURERS PROFILED
4.1 Roche
4.1.1 Roche Company Information
4.1.2 Roche Business Overview
4.1.3 Roche Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.1.4 Roche Biologics and Biosimilars Product Portfolio
4.1.5 Roche Recent Developments
4.2 Amgen
4.2.1 Amgen Company Information
4.2.2 Amgen Business Overview
4.2.3 Amgen Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.2.4 Amgen Biologics and Biosimilars Product Portfolio
4.2.5 Amgen Recent Developments
4.3 AbbVie
4.3.1 AbbVie Company Information
4.3.2 AbbVie Business Overview
4.3.3 AbbVie Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.3.4 AbbVie Biologics and Biosimilars Product Portfolio
4.3.5 AbbVie Recent Developments
4.4 Sanofi-Aventis
4.4.1 Sanofi-Aventis Company Information
4.4.2 Sanofi-Aventis Business Overview
4.4.3 Sanofi-Aventis Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.4.4 Sanofi-Aventis Biologics and Biosimilars Product Portfolio
4.4.5 Sanofi-Aventis Recent Developments
4.5 Johnson & Johnson
4.5.1 Johnson & Johnson Company Information
4.5.2 Johnson & Johnson Business Overview
4.5.3 Johnson & Johnson Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.5.4 Johnson & Johnson Biologics and Biosimilars Product Portfolio
4.5.5 Johnson & Johnson Recent Developments
4.6 Pfizer
4.6.1 Pfizer Company Information
4.6.2 Pfizer Business Overview
4.6.3 Pfizer Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.6.4 Pfizer Biologics and Biosimilars Product Portfolio
4.6.5 Pfizer Recent Developments
4.7 Novo Nordisk
4.7.1 Novo Nordisk Company Information
4.7.2 Novo Nordisk Business Overview
4.7.3 Novo Nordisk Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.7.4 Novo Nordisk Biologics and Biosimilars Product Portfolio
4.7.5 Novo Nordisk Recent Developments
4.8 Eli Lilly
4.8.1 Eli Lilly Company Information
4.8.2 Eli Lilly Business Overview
4.8.3 Eli Lilly Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.8.4 Eli Lilly Biologics and Biosimilars Product Portfolio
4.8.5 Eli Lilly Recent Developments
4.9 Novartis
4.9.1 Novartis Company Information
4.9.2 Novartis Business Overview
4.9.3 Novartis Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.9.4 Novartis Biologics and Biosimilars Product Portfolio
4.9.5 Novartis Recent Developments
4.10 Merck
4.10.1 Merck Company Information
4.10.2 Merck Business Overview
4.10.3 Merck Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.10.4 Merck Biologics and Biosimilars Product Portfolio
4.10.5 Merck Recent Developments
4.11 3sbio
4.11.1 3sbio Company Information
4.11.2 3sbio Business Overview
4.11.3 3sbio Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.11.4 3sbio Biologics and Biosimilars Product Portfolio
4.11.5 3sbio Recent Developments
4.12 Changchun High Tech
4.12.1 Changchun High Tech Company Information
4.12.2 Changchun High Tech Business Overview
4.12.3 Changchun High Tech Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.12.4 Changchun High Tech Biologics and Biosimilars Product Portfolio
4.12.5 Changchun High Tech Recent Developments
4.13 CP Guojian
4.13.1 CP Guojian Company Information
4.13.2 CP Guojian Business Overview
4.13.3 CP Guojian Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.13.4 CP Guojian Biologics and Biosimilars Product Portfolio
4.13.5 CP Guojian Recent Developments
4.14 Biotech
4.14.1 Biotech Company Information
4.14.2 Biotech Business Overview
4.14.3 Biotech Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.14.4 Biotech Biologics and Biosimilars Product Portfolio
4.14.5 Biotech Recent Developments
4.15 Gelgen
4.15.1 Gelgen Company Information
4.15.2 Gelgen Business Overview
4.15.3 Gelgen Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.15.4 Gelgen Biologics and Biosimilars Product Portfolio
4.15.5 Gelgen Recent Developments
4.16 Innovent
4.16.1 Innovent Company Information
4.16.2 Innovent Business Overview
4.16.3 Innovent Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.16.4 Innovent Biologics and Biosimilars Product Portfolio
4.16.5 Innovent Recent Developments
4.17 Dong Bao
4.17.1 Dong Bao Company Information
4.17.2 Dong Bao Business Overview
4.17.3 Dong Bao Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.17.4 Dong Bao Biologics and Biosimilars Product Portfolio
4.17.5 Dong Bao Recent Developments
4.18 Ganlee
4.18.1 Ganlee Company Information
4.18.2 Ganlee Business Overview
4.18.3 Ganlee Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.18.4 Ganlee Biologics and Biosimilars Product Portfolio
4.18.5 Ganlee Recent Developments
4.19 United Laboratories
4.19.1 United Laboratories Company Information
4.19.2 United Laboratories Business Overview
4.19.3 United Laboratories Biologics and Biosimilars Sales, Revenue and Gross Margin (2019-2024)
4.19.4 United Laboratories Biologics and Biosimilars Product Portfolio
4.19.5 United Laboratories Recent Developments
5 GLOBAL BIOLOGICS AND BIOSIMILARS MARKET SCENARIO BY REGION
5.1 Global Biologics and Biosimilars Market Size by Region: 2019 VS 2023 VS 2030
5.2 Global Biologics and Biosimilars Sales by Region: 2019-2030
5.2.1 Global Biologics and Biosimilars Sales by Region: 2019-2024
5.2.2 Global Biologics and Biosimilars Sales by Region: 2025-2030
5.3 Global Biologics and Biosimilars Revenue by Region: 2019-2030
5.3.1 Global Biologics and Biosimilars Revenue by Region: 2019-2024
5.3.2 Global Biologics and Biosimilars Revenue by Region: 2025-2030
5.4 North America Biologics and Biosimilars Market Facts & Figures by Country
5.4.1 North America Biologics and Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
5.4.2 North America Biologics and Biosimilars Sales by Country (2019-2030)
5.4.3 North America Biologics and Biosimilars Revenue by Country (2019-2030)
5.4.4 U.S.
5.4.5 Canada
5.5 Europe Biologics and Biosimilars Market Facts & Figures by Country
5.5.1 Europe Biologics and Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
5.5.2 Europe Biologics and Biosimilars Sales by Country (2019-2030)
5.5.3 Europe Biologics and Biosimilars Revenue by Country (2019-2030)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.6 Asia Pacific Biologics and Biosimilars Market Facts & Figures by Country
5.6.1 Asia Pacific Biologics and Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
5.6.2 Asia Pacific Biologics and Biosimilars Sales by Country (2019-2030)
5.6.3 Asia Pacific Biologics and Biosimilars Revenue by Country (2019-2030)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Indonesia
5.6.11 Thailand
5.6.12 Malaysia
5.7 Latin America Biologics and Biosimilars Market Facts & Figures by Country
5.7.1 Latin America Biologics and Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
5.7.2 Latin America Biologics and Biosimilars Sales by Country (2019-2030)
5.7.3 Latin America Biologics and Biosimilars Revenue by Country (2019-2030)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa Biologics and Biosimilars Market Facts & Figures by Country
5.8.1 Middle East and Africa Biologics and Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
5.8.2 Middle East and Africa Biologics and Biosimilars Sales by Country (2019-2030)
5.8.3 Middle East and Africa Biologics and Biosimilars Revenue by Country (2019-2030)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 SEGMENT BY TYPE
6.1 Global Biologics and Biosimilars Sales by Type (2019-2030)
6.1.1 Global Biologics and Biosimilars Sales by Type (2019-2030) & (K Units)
6.1.2 Global Biologics and Biosimilars Sales Market Share by Type (2019-2030)
6.2 Global Biologics and Biosimilars Revenue by Type (2019-2030)
6.2.1 Global Biologics and Biosimilars Sales by Type (2019-2030) & (US$ Million)
6.2.2 Global Biologics and Biosimilars Revenue Market Share by Type (2019-2030)
6.3 Global Biologics and Biosimilars Price by Type (2019-2030)
7 SEGMENT BY APPLICATION
7.1 Global Biologics and Biosimilars Sales by Application (2019-2030)
7.1.1 Global Biologics and Biosimilars Sales by Application (2019-2030) & (K Units)
7.1.2 Global Biologics and Biosimilars Sales Market Share by Application (2019-2030)
7.2 Global Biologics and Biosimilars Revenue by Application (2019-2030)
7.2.1 Global Biologics and Biosimilars Sales by Application (2019-2030) & (US$ Million)
7.2.2 Global Biologics and Biosimilars Revenue Market Share by Application (2019-2030)
7.3 Global Biologics and Biosimilars Price by Application (2019-2030)
8 VALUE CHAIN AND SALES CHANNELS ANALYSIS OF THE MARKET
8.1 Biologics and Biosimilars Value Chain Analysis
8.1.1 Biologics and Biosimilars Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Biologics and Biosimilars Production Mode & Process
8.2 Biologics and Biosimilars Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Biologics and Biosimilars Distributors
8.2.3 Biologics and Biosimilars Customers
9 GLOBAL BIOLOGICS AND BIOSIMILARS ANALYZING MARKET DYNAMICS
9.1 Biologics and Biosimilars Industry Trends
9.2 Biologics and Biosimilars Industry Drivers
9.3 Biologics and Biosimilars Industry Opportunities and Challenges
9.4 Biologics and Biosimilars Industry Restraints
10 REPORT CONCLUSION
11 DISCLAIMER
LIST OF TABLES
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US$ Million)
Table 4. Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US$ Million)
Table 5. Global Biologics and Biosimilars Volume and Revenue Market Size and CAGR of Manufacturers (2018 Versus 2022)
Table 6. Global Biologics and Biosimilars Sales (K Units) of Manufacturers (2018-2023)
Table 7. Global Biologics and Biosimilars Sales Market Share by Manufacturers (2018-2023)
Table 8. Global Biologics and Biosimilars Revenue of Manufacturers (2018-2023)
Table 9. Global Biologics and Biosimilars Revenue Share by Manufacturers (2018-2023)
Table 10. Global Market Biologics and Biosimilars Average Price (USD/Unit) of Manufacturers (2018-2023)
Table 11. Global Biologics and Biosimilars Industry Ranking, 2021 VS 2022 VS 2023
Table 12. Global Manufacturers of Biologics and Biosimilars, Product Type & Application
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Biologics and Biosimilars by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 16. Roche Company Information
Table 17. Roche Business Overview
Table 18. Roche Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 19. Roche Biologics and Biosimilars Product Portfolio
Table 20. Roche Recent Developments
Table 21. Amgen Company Information
Table 22. Amgen Business Overview
Table 23. Amgen Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 24. Amgen Biologics and Biosimilars Product Portfolio
Table 25. Amgen Recent Developments
Table 26. AbbVie Company Information
Table 27. AbbVie Business Overview
Table 28. AbbVie Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 29. AbbVie Biologics and Biosimilars Product Portfolio
Table 30. AbbVie Recent Developments
Table 31. Sanofi-Aventis Company Information
Table 32. Sanofi-Aventis Business Overview
Table 33. Sanofi-Aventis Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 34. Sanofi-Aventis Biologics and Biosimilars Product Portfolio
Table 35. Sanofi-Aventis Recent Developments
Table 36. Johnson & Johnson Company Information
Table 37. Johnson & Johnson Business Overview
Table 38. Johnson & Johnson Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 39. Johnson & Johnson Biologics and Biosimilars Product Portfolio
Table 40. Johnson & Johnson Recent Developments
Table 41. Pfizer Company Information
Table 42. Pfizer Business Overview
Table 43. Pfizer Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 44. Pfizer Biologics and Biosimilars Product Portfolio
Table 45. Pfizer Recent Developments
Table 46. Novo Nordisk Company Information
Table 47. Novo Nordisk Business Overview
Table 48. Novo Nordisk Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 49. Novo Nordisk Biologics and Biosimilars Product Portfolio
Table 50. Novo Nordisk Recent Developments
Table 51. Eli Lilly Company Information
Table 52. Eli Lilly Business Overview
Table 53. Eli Lilly Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 54. Eli Lilly Biologics and Biosimilars Product Portfolio
Table 55. Eli Lilly Recent Developments
Table 56. Novartis Company Information
Table 57. Novartis Business Overview
Table 58. Novartis Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 59. Novartis Biologics and Biosimilars Product Portfolio
Table 60. Novartis Recent Developments
Table 61. Merck Company Information
Table 62. Merck Business Overview
Table 63. Merck Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 64. Merck Biologics and Biosimilars Product Portfolio
Table 65. Merck Recent Developments
Table 66. 3sbio Company Information
Table 67. 3sbio Business Overview
Table 68. 3sbio Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 69. 3sbio Biologics and Biosimilars Product Portfolio
Table 70. 3sbio Recent Developments
Table 71. Changchun High Tech Company Information
Table 72. Changchun High Tech Business Overview
Table 73. Changchun High Tech Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 74. Changchun High Tech Biologics and Biosimilars Product Portfolio
Table 75. Changchun High Tech Recent Developments
Table 76. CP Guojian Company Information
Table 77. CP Guojian Business Overview
Table 78. CP Guojian Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 79. CP Guojian Biologics and Biosimilars Product Portfolio
Table 80. CP Guojian Recent Developments
Table 81. Biotech Company Information
Table 82. Biotech Business Overview
Table 83. Biotech Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 84. Biotech Biologics and Biosimilars Product Portfolio
Table 85. Biotech Recent Developments
Table 86. Gelgen Company Information
Table 87. Gelgen Business Overview
Table 88. Gelgen Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 89. Gelgen Biologics and Biosimilars Product Portfolio
Table 90. Gelgen Recent Developments
Table 91. Innovent Company Information
Table 92. Innovent Business Overview
Table 93. Innovent Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 94. Innovent Biologics and Biosimilars Product Portfolio
Table 95. Innovent Recent Developments
Table 96. Dong Bao Company Information
Table 97. Dong Bao Business Overview
Table 98. Dong Bao Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 99. Dong Bao Biologics and Biosimilars Product Portfolio
Table 100. Dong Bao Recent Developments
Table 101. Ganlee Company Information
Table 102. Ganlee Business Overview
Table 103. Ganlee Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 104. Ganlee Biologics and Biosimilars Product Portfolio
Table 105. Ganlee Recent Developments
Table 106. United Laboratories Company Information
Table 107. United Laboratories Business Overview
Table 108. United Laboratories Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 109. United Laboratories Biologics and Biosimilars Product Portfolio
Table 110. United Laboratories Recent Developments
Table 111. Global Biologics and Biosimilars Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 112. Global Biologics and Biosimilars Sales by Region (2018-2023) & (K Units)
Table 113. Global Biologics and Biosimilars Sales Market Share by Region (2018-2023)
Table 114. Global Biologics and Biosimilars Sales by Region (2024-2029) & (K Units)
Table 115. Global Biologics and Biosimilars Sales Market Share by Region (2024-2029)
Table 116. Global Biologics and Biosimilars Revenue by Region (2018-2023) & (US$ Million)
Table 117. Global Biologics and Biosimilars Revenue Market Share by Region (2018-2023)
Table 118. Global Biologics and Biosimilars Revenue by Region (2024-2029) & (US$ Million)
Table 119. Global Biologics and Biosimilars Revenue Market Share by Region (2024-2029)
Table 120. North America Biologics and Biosimilars Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 121. North America Biologics and Biosimilars Sales by Country (2018-2023) & (K Units)
Table 122. North America Biologics and Biosimilars Sales by Country (2024-2029) & (K Units)
Table 123. North America Biologics and Biosimilars Revenue by Country (2018-2023) & (US$ Million)
Table 124. North America Biologics and Biosimilars Revenue by Country (2024-2029) & (US$ Million)
Table 125. Europe Biologics and Biosimilars Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 126. Europe Biologics and Biosimilars Sales by Country (2018-2023) & (K Units)
Table 127. Europe Biologics and Biosimilars Sales by Country (2024-2029) & (K Units)
Table 128. Europe Biologics and Biosimilars Revenue by Country (2018-2023) & (US$ Million)
Table 129. Europe Biologics and Biosimilars Revenue by Country (2024-2029) & (US$ Million)
Table 130. Asia Pacific Biologics and Biosimilars Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 131. Asia Pacific Biologics and Biosimilars Sales by Country (2018-2023) & (K Units)
Table 132. Asia Pacific Biologics and Biosimilars Sales by Country (2024-2029) & (K Units)
Table 133. Asia Pacific Biologics and Biosimilars Revenue by Country (2018-2023) & (US$ Million)
Table 134. Asia Pacific Biologics and Biosimilars Revenue by Country (2024-2029) & (US$ Million)
Table 135. Latin America Biologics and Biosimilars Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 136. Latin America Biologics and Biosimilars Sales by Country (2018-2023) & (K Units)
Table 137. Latin America Biologics and Biosimilars Sales by Country (2024-2029) & (K Units)
Table 138. Latin America Biologics and Biosimilars Revenue by Country (2018-2023) & (US$ Million)
Table 139. Latin America Biologics and Biosimilars Revenue by Country (2024-2029) & (US$ Million)
Table 140. Middle East and Africa Biologics and Biosimilars Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 141. Middle East and Africa Biologics and Biosimilars Sales by Country (2018-2023) & (K Units)
Table 142. Middle East and Africa Biologics and Biosimilars Sales by Country (2024-2029) & (K Units)
Table 143. Middle East and Africa Biologics and Biosimilars Revenue by Country (2018-2023) & (US$ Million)
Table 144. Middle East and Africa Biologics and Biosimilars Revenue by Country (2024-2029) & (US$ Million)
Table 145. Global Biologics and Biosimilars Sales by Type (2018-2023) & (K Units)
Table 146. Global Biologics and Biosimilars Sales by Type (2024-2029) & (K Units)
Table 147. Global Biologics and Biosimilars Sales Market Share by Type (2018-2023)
Table 148. Global Biologics and Biosimilars Sales Market Share by Type (2024-2029)
Table 149. Global Biologics and Biosimilars Revenue by Type (2018-2023) & (US$ Million)
Table 150. Global Biologics and Biosimilars Revenue by Type (2024-2029) & (US$ Million)
Table 151. Global Biologics and Biosimilars Revenue Market Share by Type (2018-2023)
Table 152. Global Biologics and Biosimilars Revenue Market Share by Type (2024-2029)
Table 153. Global Biologics and Biosimilars Price by Type (2018-2023) & (USD/Unit)
Table 154. Global Biologics and Biosimilars Price by Type (2024-2029) & (USD/Unit)
Table 155. Global Biologics and Biosimilars Sales by Application (2018-2023) & (K Units)
Table 156. Global Biologics and Biosimilars Sales by Application (2024-2029) & (K Units)
Table 157. Global Biologics and Biosimilars Sales Market Share by Application (2018-2023)
Table 158. Global Biologics and Biosimilars Sales Market Share by Application (2024-2029)
Table 159. Global Biologics and Biosimilars Revenue by Application (2018-2023) & (US$ Million)
Table 160. Global Biologics and Biosimilars Revenue by Application (2024-2029) & (US$ Million)
Table 161. Global Biologics and Biosimilars Revenue Market Share by Application (2018-2023)
Table 162. Global Biologics and Biosimilars Revenue Market Share by Application (2024-2029)
Table 163. Global Biologics and Biosimilars Price by Application (2018-2023) & (USD/Unit)
Table 164. Global Biologics and Biosimilars Price by Application (2024-2029) & (USD/Unit)
Table 165. Key Raw Materials
Table 166. Raw Materials Key Suppliers
Table 167. Biologics and Biosimilars Distributors List
Table 168. Biologics and Biosimilars Customers List
Table 169. Biologics and Biosimilars Industry Trends
Table 170. Biologics and Biosimilars Industry Drivers
Table 171. Biologics and Biosimilars Industry Restraints
Table 172. Authors List of This Report
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US$ Million)
Table 4. Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US$ Million)
Table 5. Global Biologics and Biosimilars Volume and Revenue Market Size and CAGR of Manufacturers (2018 Versus 2022)
Table 6. Global Biologics and Biosimilars Sales (K Units) of Manufacturers (2018-2023)
Table 7. Global Biologics and Biosimilars Sales Market Share by Manufacturers (2018-2023)
Table 8. Global Biologics and Biosimilars Revenue of Manufacturers (2018-2023)
Table 9. Global Biologics and Biosimilars Revenue Share by Manufacturers (2018-2023)
Table 10. Global Market Biologics and Biosimilars Average Price (USD/Unit) of Manufacturers (2018-2023)
Table 11. Global Biologics and Biosimilars Industry Ranking, 2021 VS 2022 VS 2023
Table 12. Global Manufacturers of Biologics and Biosimilars, Product Type & Application
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Biologics and Biosimilars by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 16. Roche Company Information
Table 17. Roche Business Overview
Table 18. Roche Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 19. Roche Biologics and Biosimilars Product Portfolio
Table 20. Roche Recent Developments
Table 21. Amgen Company Information
Table 22. Amgen Business Overview
Table 23. Amgen Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 24. Amgen Biologics and Biosimilars Product Portfolio
Table 25. Amgen Recent Developments
Table 26. AbbVie Company Information
Table 27. AbbVie Business Overview
Table 28. AbbVie Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 29. AbbVie Biologics and Biosimilars Product Portfolio
Table 30. AbbVie Recent Developments
Table 31. Sanofi-Aventis Company Information
Table 32. Sanofi-Aventis Business Overview
Table 33. Sanofi-Aventis Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 34. Sanofi-Aventis Biologics and Biosimilars Product Portfolio
Table 35. Sanofi-Aventis Recent Developments
Table 36. Johnson & Johnson Company Information
Table 37. Johnson & Johnson Business Overview
Table 38. Johnson & Johnson Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 39. Johnson & Johnson Biologics and Biosimilars Product Portfolio
Table 40. Johnson & Johnson Recent Developments
Table 41. Pfizer Company Information
Table 42. Pfizer Business Overview
Table 43. Pfizer Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 44. Pfizer Biologics and Biosimilars Product Portfolio
Table 45. Pfizer Recent Developments
Table 46. Novo Nordisk Company Information
Table 47. Novo Nordisk Business Overview
Table 48. Novo Nordisk Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 49. Novo Nordisk Biologics and Biosimilars Product Portfolio
Table 50. Novo Nordisk Recent Developments
Table 51. Eli Lilly Company Information
Table 52. Eli Lilly Business Overview
Table 53. Eli Lilly Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 54. Eli Lilly Biologics and Biosimilars Product Portfolio
Table 55. Eli Lilly Recent Developments
Table 56. Novartis Company Information
Table 57. Novartis Business Overview
Table 58. Novartis Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 59. Novartis Biologics and Biosimilars Product Portfolio
Table 60. Novartis Recent Developments
Table 61. Merck Company Information
Table 62. Merck Business Overview
Table 63. Merck Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 64. Merck Biologics and Biosimilars Product Portfolio
Table 65. Merck Recent Developments
Table 66. 3sbio Company Information
Table 67. 3sbio Business Overview
Table 68. 3sbio Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 69. 3sbio Biologics and Biosimilars Product Portfolio
Table 70. 3sbio Recent Developments
Table 71. Changchun High Tech Company Information
Table 72. Changchun High Tech Business Overview
Table 73. Changchun High Tech Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 74. Changchun High Tech Biologics and Biosimilars Product Portfolio
Table 75. Changchun High Tech Recent Developments
Table 76. CP Guojian Company Information
Table 77. CP Guojian Business Overview
Table 78. CP Guojian Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 79. CP Guojian Biologics and Biosimilars Product Portfolio
Table 80. CP Guojian Recent Developments
Table 81. Biotech Company Information
Table 82. Biotech Business Overview
Table 83. Biotech Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 84. Biotech Biologics and Biosimilars Product Portfolio
Table 85. Biotech Recent Developments
Table 86. Gelgen Company Information
Table 87. Gelgen Business Overview
Table 88. Gelgen Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 89. Gelgen Biologics and Biosimilars Product Portfolio
Table 90. Gelgen Recent Developments
Table 91. Innovent Company Information
Table 92. Innovent Business Overview
Table 93. Innovent Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 94. Innovent Biologics and Biosimilars Product Portfolio
Table 95. Innovent Recent Developments
Table 96. Dong Bao Company Information
Table 97. Dong Bao Business Overview
Table 98. Dong Bao Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 99. Dong Bao Biologics and Biosimilars Product Portfolio
Table 100. Dong Bao Recent Developments
Table 101. Ganlee Company Information
Table 102. Ganlee Business Overview
Table 103. Ganlee Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 104. Ganlee Biologics and Biosimilars Product Portfolio
Table 105. Ganlee Recent Developments
Table 106. United Laboratories Company Information
Table 107. United Laboratories Business Overview
Table 108. United Laboratories Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 109. United Laboratories Biologics and Biosimilars Product Portfolio
Table 110. United Laboratories Recent Developments
Table 111. Global Biologics and Biosimilars Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 112. Global Biologics and Biosimilars Sales by Region (2018-2023) & (K Units)
Table 113. Global Biologics and Biosimilars Sales Market Share by Region (2018-2023)
Table 114. Global Biologics and Biosimilars Sales by Region (2024-2029) & (K Units)
Table 115. Global Biologics and Biosimilars Sales Market Share by Region (2024-2029)
Table 116. Global Biologics and Biosimilars Revenue by Region (2018-2023) & (US$ Million)
Table 117. Global Biologics and Biosimilars Revenue Market Share by Region (2018-2023)
Table 118. Global Biologics and Biosimilars Revenue by Region (2024-2029) & (US$ Million)
Table 119. Global Biologics and Biosimilars Revenue Market Share by Region (2024-2029)
Table 120. North America Biologics and Biosimilars Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 121. North America Biologics and Biosimilars Sales by Country (2018-2023) & (K Units)
Table 122. North America Biologics and Biosimilars Sales by Country (2024-2029) & (K Units)
Table 123. North America Biologics and Biosimilars Revenue by Country (2018-2023) & (US$ Million)
Table 124. North America Biologics and Biosimilars Revenue by Country (2024-2029) & (US$ Million)
Table 125. Europe Biologics and Biosimilars Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 126. Europe Biologics and Biosimilars Sales by Country (2018-2023) & (K Units)
Table 127. Europe Biologics and Biosimilars Sales by Country (2024-2029) & (K Units)
Table 128. Europe Biologics and Biosimilars Revenue by Country (2018-2023) & (US$ Million)
Table 129. Europe Biologics and Biosimilars Revenue by Country (2024-2029) & (US$ Million)
Table 130. Asia Pacific Biologics and Biosimilars Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 131. Asia Pacific Biologics and Biosimilars Sales by Country (2018-2023) & (K Units)
Table 132. Asia Pacific Biologics and Biosimilars Sales by Country (2024-2029) & (K Units)
Table 133. Asia Pacific Biologics and Biosimilars Revenue by Country (2018-2023) & (US$ Million)
Table 134. Asia Pacific Biologics and Biosimilars Revenue by Country (2024-2029) & (US$ Million)
Table 135. Latin America Biologics and Biosimilars Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 136. Latin America Biologics and Biosimilars Sales by Country (2018-2023) & (K Units)
Table 137. Latin America Biologics and Biosimilars Sales by Country (2024-2029) & (K Units)
Table 138. Latin America Biologics and Biosimilars Revenue by Country (2018-2023) & (US$ Million)
Table 139. Latin America Biologics and Biosimilars Revenue by Country (2024-2029) & (US$ Million)
Table 140. Middle East and Africa Biologics and Biosimilars Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 141. Middle East and Africa Biologics and Biosimilars Sales by Country (2018-2023) & (K Units)
Table 142. Middle East and Africa Biologics and Biosimilars Sales by Country (2024-2029) & (K Units)
Table 143. Middle East and Africa Biologics and Biosimilars Revenue by Country (2018-2023) & (US$ Million)
Table 144. Middle East and Africa Biologics and Biosimilars Revenue by Country (2024-2029) & (US$ Million)
Table 145. Global Biologics and Biosimilars Sales by Type (2018-2023) & (K Units)
Table 146. Global Biologics and Biosimilars Sales by Type (2024-2029) & (K Units)
Table 147. Global Biologics and Biosimilars Sales Market Share by Type (2018-2023)
Table 148. Global Biologics and Biosimilars Sales Market Share by Type (2024-2029)
Table 149. Global Biologics and Biosimilars Revenue by Type (2018-2023) & (US$ Million)
Table 150. Global Biologics and Biosimilars Revenue by Type (2024-2029) & (US$ Million)
Table 151. Global Biologics and Biosimilars Revenue Market Share by Type (2018-2023)
Table 152. Global Biologics and Biosimilars Revenue Market Share by Type (2024-2029)
Table 153. Global Biologics and Biosimilars Price by Type (2018-2023) & (USD/Unit)
Table 154. Global Biologics and Biosimilars Price by Type (2024-2029) & (USD/Unit)
Table 155. Global Biologics and Biosimilars Sales by Application (2018-2023) & (K Units)
Table 156. Global Biologics and Biosimilars Sales by Application (2024-2029) & (K Units)
Table 157. Global Biologics and Biosimilars Sales Market Share by Application (2018-2023)
Table 158. Global Biologics and Biosimilars Sales Market Share by Application (2024-2029)
Table 159. Global Biologics and Biosimilars Revenue by Application (2018-2023) & (US$ Million)
Table 160. Global Biologics and Biosimilars Revenue by Application (2024-2029) & (US$ Million)
Table 161. Global Biologics and Biosimilars Revenue Market Share by Application (2018-2023)
Table 162. Global Biologics and Biosimilars Revenue Market Share by Application (2024-2029)
Table 163. Global Biologics and Biosimilars Price by Application (2018-2023) & (USD/Unit)
Table 164. Global Biologics and Biosimilars Price by Application (2024-2029) & (USD/Unit)
Table 165. Key Raw Materials
Table 166. Raw Materials Key Suppliers
Table 167. Biologics and Biosimilars Distributors List
Table 168. Biologics and Biosimilars Customers List
Table 169. Biologics and Biosimilars Industry Trends
Table 170. Biologics and Biosimilars Industry Drivers
Table 171. Biologics and Biosimilars Industry Restraints
Table 172. Authors List of This Report
LIST OF FIGURES
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Biologics and BiosimilarsProduct Picture
Figure 5. Global Biologics and Biosimilars Revenue (US$ Million), 2018 VS 2022 VS 2029
Figure 6. Global Biologics and Biosimilars Market Size (2018-2029) & (US$ Million)
Figure 7. Global Biologics and Biosimilars Sales (2018-2029) & (K Units)
Figure 8. Global Biologics and Biosimilars Average Price (USD/Unit) & (2018-2029)
Figure 9. Monoclonal Antibodies Product Picture
Figure 10. Interferon Product Picture
Figure 11. Erythropoietin Product Picture
Figure 12. Insulin Product Picture
Figure 13. Vaccines Product Picture
Figure 14. Others Product Picture
Figure 15. Tumor Product Picture
Figure 16. Diabetes Product Picture
Figure 17. Cardiovascular Product Picture
Figure 18. Hemophilia Product Picture
Figure 19. Others Product Picture
Figure 20. Global Biologics and Biosimilars Revenue Share by Manufacturers in 2022
Figure 21. Global Manufacturers of Biologics and Biosimilars, Manufacturing Sites & Headquarters
Figure 22. Global Manufacturers of Biologics and Biosimilars, Date of Enter into This Industry
Figure 23. Global Top 5 and 10 Biologics and Biosimilars Players Market Share by Revenue in 2022
Figure 24. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 25. Global Biologics and Biosimilars Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 26. Global Biologics and Biosimilars Sales by Region in 2022
Figure 27. Global Biologics and Biosimilars Revenue by Region in 2022
Figure 28. North America Biologics and Biosimilars Market Size by Country in 2022
Figure 29. North America Biologics and Biosimilars Sales Market Share by Country (2018-2029)
Figure 30. North America Biologics and Biosimilars Revenue Market Share by Country (2018-2029)
Figure 31. U.S. Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Canada Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Europe Biologics and Biosimilars Market Size by Country in 2022
Figure 34. Europe Biologics and Biosimilars Sales Market Share by Country (2018-2029)
Figure 35. Europe Biologics and Biosimilars Revenue Market Share by Country (2018-2029)
Figure 36. Germany Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. France Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. U.K. Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Italy Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Russia Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Asia Pacific Biologics and Biosimilars Market Size by Country in 2022
Figure 42. Asia Pacific Biologics and Biosimilars Sales Market Share by Country (2018-2029)
Figure 43. Asia Pacific Biologics and Biosimilars Revenue Market Share by Country (2018-2029)
Figure 44. China Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Japan Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. South Korea Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. India Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Australia Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. China Taiwan Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Indonesia Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 51. Thailand Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Malaysia Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Latin America Biologics and Biosimilars Market Size by Country in 2022
Figure 54. Latin America Biologics and Biosimilars Sales Market Share by Country (2018-2029)
Figure 55. Latin America Biologics and Biosimilars Revenue Market Share by Country (2018-2029)
Figure 56. Mexico Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 57. Brazil Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 58. Argentina Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 59. Middle East and Africa Biologics and Biosimilars Market Size by Country in 2022
Figure 60. Middle East and Africa Biologics and Biosimilars Sales Market Share by Country (2018-2029)
Figure 61. Middle East and Africa Biologics and Biosimilars Revenue Market Share by Country (2018-2029)
Figure 62. Turkey Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 63. Saudi Arabia Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 64. UAE Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 65. Global Biologics and Biosimilars Sales Market Share by Type (2018-2029)
Figure 66. Global Biologics and Biosimilars Revenue Market Share by Type (2018-2029)
Figure 67. Global Biologics and Biosimilars Price (USD/Unit) by Type (2018-2029)
Figure 68. Global Biologics and Biosimilars Sales Market Share by Application (2018-2029)
Figure 69. Global Biologics and Biosimilars Revenue Market Share by Application (2018-2029)
Figure 70. Global Biologics and Biosimilars Price (USD/Unit) by Application (2018-2029)
Figure 71. Biologics and Biosimilars Value Chain
Figure 72. Biologics and Biosimilars Production Mode & Process
Figure 73. Direct Comparison with Distribution Share
Figure 74. Distributors Profiles
Figure 75. Biologics and Biosimilars Industry Opportunities and Challenges
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Biologics and BiosimilarsProduct Picture
Figure 5. Global Biologics and Biosimilars Revenue (US$ Million), 2018 VS 2022 VS 2029
Figure 6. Global Biologics and Biosimilars Market Size (2018-2029) & (US$ Million)
Figure 7. Global Biologics and Biosimilars Sales (2018-2029) & (K Units)
Figure 8. Global Biologics and Biosimilars Average Price (USD/Unit) & (2018-2029)
Figure 9. Monoclonal Antibodies Product Picture
Figure 10. Interferon Product Picture
Figure 11. Erythropoietin Product Picture
Figure 12. Insulin Product Picture
Figure 13. Vaccines Product Picture
Figure 14. Others Product Picture
Figure 15. Tumor Product Picture
Figure 16. Diabetes Product Picture
Figure 17. Cardiovascular Product Picture
Figure 18. Hemophilia Product Picture
Figure 19. Others Product Picture
Figure 20. Global Biologics and Biosimilars Revenue Share by Manufacturers in 2022
Figure 21. Global Manufacturers of Biologics and Biosimilars, Manufacturing Sites & Headquarters
Figure 22. Global Manufacturers of Biologics and Biosimilars, Date of Enter into This Industry
Figure 23. Global Top 5 and 10 Biologics and Biosimilars Players Market Share by Revenue in 2022
Figure 24. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 25. Global Biologics and Biosimilars Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 26. Global Biologics and Biosimilars Sales by Region in 2022
Figure 27. Global Biologics and Biosimilars Revenue by Region in 2022
Figure 28. North America Biologics and Biosimilars Market Size by Country in 2022
Figure 29. North America Biologics and Biosimilars Sales Market Share by Country (2018-2029)
Figure 30. North America Biologics and Biosimilars Revenue Market Share by Country (2018-2029)
Figure 31. U.S. Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Canada Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Europe Biologics and Biosimilars Market Size by Country in 2022
Figure 34. Europe Biologics and Biosimilars Sales Market Share by Country (2018-2029)
Figure 35. Europe Biologics and Biosimilars Revenue Market Share by Country (2018-2029)
Figure 36. Germany Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. France Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. U.K. Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Italy Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Russia Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Asia Pacific Biologics and Biosimilars Market Size by Country in 2022
Figure 42. Asia Pacific Biologics and Biosimilars Sales Market Share by Country (2018-2029)
Figure 43. Asia Pacific Biologics and Biosimilars Revenue Market Share by Country (2018-2029)
Figure 44. China Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Japan Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. South Korea Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. India Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Australia Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. China Taiwan Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Indonesia Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 51. Thailand Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Malaysia Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Latin America Biologics and Biosimilars Market Size by Country in 2022
Figure 54. Latin America Biologics and Biosimilars Sales Market Share by Country (2018-2029)
Figure 55. Latin America Biologics and Biosimilars Revenue Market Share by Country (2018-2029)
Figure 56. Mexico Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 57. Brazil Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 58. Argentina Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 59. Middle East and Africa Biologics and Biosimilars Market Size by Country in 2022
Figure 60. Middle East and Africa Biologics and Biosimilars Sales Market Share by Country (2018-2029)
Figure 61. Middle East and Africa Biologics and Biosimilars Revenue Market Share by Country (2018-2029)
Figure 62. Turkey Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 63. Saudi Arabia Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 64. UAE Biologics and Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 65. Global Biologics and Biosimilars Sales Market Share by Type (2018-2029)
Figure 66. Global Biologics and Biosimilars Revenue Market Share by Type (2018-2029)
Figure 67. Global Biologics and Biosimilars Price (USD/Unit) by Type (2018-2029)
Figure 68. Global Biologics and Biosimilars Sales Market Share by Application (2018-2029)
Figure 69. Global Biologics and Biosimilars Revenue Market Share by Application (2018-2029)
Figure 70. Global Biologics and Biosimilars Price (USD/Unit) by Application (2018-2029)
Figure 71. Biologics and Biosimilars Value Chain
Figure 72. Biologics and Biosimilars Production Mode & Process
Figure 73. Direct Comparison with Distribution Share
Figure 74. Distributors Profiles
Figure 75. Biologics and Biosimilars Industry Opportunities and Challenges
